SCHEMBL613171

SCHEMBL613171

CCCCCCCCCN(C)CC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 3/20 0.60
S1PR2 O95136 1/20 0.50
S1PR1 P21453 1/20 0.50
S1PR3 Q99500 1/20 0.50
S1PR5 Q9H228 1/20 0.50
TSHR P16473 2/20 0.47
THRB P10828 1/20 0.47
GGPS1 O95749 4/20 0.47
CHRM2 P08172 1/20 0.43
MGLL Q99685 1/20 0.41
KDM5A P29375 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
PHF8 Q9UPP1 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
FDPS P14324 1/20 0.41
AGTR1 P30556 1/20 0.41
OPRM1 P35372 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21558 1.00 DNM1 (0.60) DNM1S1PR2S1PR1S1PR3S1PR5
SCHEMBL5440531 1.00 DNM1 (0.60) DNM1S1PR2S1PR1S1PR3S1PR5
SCHEMBL15966132 1.00 DNM1 (0.60) DNM1S1PR2S1PR1S1PR3S1PR5
Octane SCHEMBL639592 1.00 DNM1 (0.60) DNM1S1PR2S1PR1S1PR3S1PR5
SCHEMBL5450820 1.00 DNM1 (0.60) DNM1S1PR2S1PR1S1PR3S1PR5
SCHEMBL669422 1.00 DNM1 (0.60) DNM1S1PR2S1PR1S1PR3S1PR5
SCHEMBL2325537 1.00 DNM1 (0.60) DNM1S1PR2S1PR1S1PR3S1PR5
SCHEMBL5450695 1.00 DNM1 (0.60) DNM1S1PR2S1PR1S1PR3S1PR5
SCHEMBL5439333 1.00 DNM1 (0.60) DNM1S1PR2S1PR1S1PR3S1PR5
SCHEMBL2129520 1.00 DNM1 (0.60) DNM1S1PR2S1PR1S1PR3S1PR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250042840-A1 PROCESS FOR PREPARING TERTIARY AMINES SPECIALTY OPERATIONS FRANCE (FR) 2025-02-06 US disclosed
EP-3538575-B1 HIGH CIS-1,4 BLOCK COPOLYMERS OF POLYBUTADIENE AND POLYISOPRENE BRIDGESTONE CORP (JP) 2024-03-13 EP disclosed
US-11884767-B2 High cis-1,4 block copolymers of polybutadiene and polyisoprene BRIDGESTONE CORPORATION (JP) 2024-01-30 US disclosed
US-20220119573-A1 HIGH CIS-1,4 BLOCK COPOLYMERS OF POLYBUTADIENE AND POLYISOPRENE BRIDGESTONE CORPORATION (JP) 2022-04-21 US disclosed
US-11230622-B2 High cis-1,4 block copolymers of polybutadiene and polyisoprene BRIDGESTONE CORPORATION (JP) 2022-01-25 US disclosed
US-10941104-B2 Biomass-derived polymers and copolymers incorporating monolignols and their derivatives THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-03-09 US disclosed
EP-3538575-A1 HIGH CIS-1,4 BLOCK COPOLYMERS OF POLYBUTADIENE AND POLYISOPRENE Bridgestone Corporation (JP) 2019-09-18 EP disclosed
CN-110139882-A High cis-1, 4 block copolymers of polybutadiene and polyisoprene 株式会社普利司通 2019-08-16 CN disclosed
WO-2018089635-A1 HIGH CIS-1,4 BLOCK COPOLYMERS OF POLYBUTADIENE AND POLYISOPRENE BRIDGESTONE CORPORATION (JP) 2018-05-17 WO disclosed
WO-2017196982-A1 BICYCLIC FUSED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF RSV GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2017-11-16 WO disclosed
CN-102405224-A Compositions comprising quaternary amino-functional organosilicon compounds, their preparation and use EVONIK DEGUSSA GMBH 2012-04-04 CN disclosed
EP-2421874-A1 COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF Evonik Degussa GmbH (DE) 2012-02-29 EP disclosed
US-20120037040-A1 COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF EVONIK DEGUSSA GMBH (DE) 2012-02-16 US disclosed
US-8053431-B2 Pharmaceutical use of substituted amides HIGH POINT PHARMACEUTICALS, LLC (US) 2011-11-08 US disclosed
WO-2010121873-A1 COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF EVONIK DEGUSSA GMBH (DE) 2010-10-28 WO disclosed
WO-2010104194-A1 BENZOFURAN DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-16 WO disclosed
US-20070043132-A1 Catalyst and process for producing a rigid polyurethane foam TOSOH CORPORATION (JP) 2007-02-22 US disclosed
US-20040082465-A1 Catalyst and process for producing a rigid polyurethane foam TOSOH CORPORATION (JP) 2004-04-29 US disclosed
EP-1382624-A1 Catalyst and process for producing a rigid polyurethane foam Tosoh Corporation (JP) 2004-01-21 EP disclosed
US-4390712-A Aqueous solution of cationic organosilicon compounds and process for the production of the solutions DEGUSSA AG (DE) 1983-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250042840-A1 PROCESS FOR PREPARING TERTIARY AMINES PNMT, TET2, HNMT DNM1 890/4885S1PR2 4510/4885S1PR1 4254/4885
US-10941104-B2 Biomass-derived polymers and copolymers incorporating monolignols and their derivatives PAOX, CBX4, COASY DNM1 2784/4885S1PR2 2439/4885S1PR1 2799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.